Efficacy of Immediate Versus Staged Complete Revascularization in Patients With NSTE-ACS and Mult… (NCT07343076) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Efficacy of Immediate Versus Staged Complete Revascularization in Patients With NSTE-ACS and Multivessel Disease (FUTURE II)
1,904 participantsStarted 2026-02-28
Plain-language summary
This is a prospective, multi-center, randomized controlled, open-label, blinded endpoint assessment study. The objective is to compare the 1-year incidence of major adverse cardiovascular and cerebrovascular events (MACCE) between two treatment strategies-immediate complete revascularization and staged complete revascularization-in NSTE-ACS patients with multivessel disease (MVD).
NSTE-ACS patients who meet other the inclusion and exclusion criteria will be randomized into the following two groups after signing an informed consent form:
Intervention group Immediate Complete Revascularization: Emergency PCI for the culprit vessel is performed successfully, and simultaneous PCI is conducted for non-culprit vessels that meet the defined criteria (visually estimated diameter ≥2.5 mm, eligible for successful PCI, and visually estimated maximum diameter stenosis ≥ 70% or positive coronary physiology testing).
Control group During emergency intervention, PCI is performed only on the culprit vessel. Elective PCI is then conducted for non-culprit vessels that meet the defined criteria (visually estimated diameter ≥ 2.5 mm, eligible for successful PCI, and visually estimated maximum diameter stenosis ≥ 70% or positive coronary physiology testing)-either during the current emergency hospitalization or within 6 weeks after the culprit vessel PCI.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Age: 18 years or older.
. Patients with intermediate-to-high risk NSTE-ACS who meet the diagnostic criteria specified in current guideline, complicated by multivessel coronary artery disease, and have successfully undergone PCI for the culprit vessel.
. PCI within 72 hours of diagnosis.
. Accompanied by multivessel disease: defined as at least one non-culprit artery that meets the following conditions: a diameter of ≥2.5 mm by visual inspection, which can be successfully subjected to PCI, and the most severe diameter stenosis rate by visual inspection is at least 70% or positive coronary physiology testing.
. Sign an informed consent form before participating in the study.
Exclusion criteria
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial is comparing doing all the blocked artery treatments at once versus spreading them out over multiple procedures — given my specific situation with multiple blocked arteries, which approach does my doctor currently think is safer for me, and how does this trial's comparison relate to that decision?
2Since this trial hasn't started recruiting yet, how long might it realistically be before I could even have the option to join, and should I be making treatment decisions now rather than waiting?
3The trial is measuring something called MACCE — major adverse cardiovascular and cerebrovascular events like heart attack and stroke — so what is my doctor's honest read on how the two strategies being studied compare in terms of those serious risks based on what's already known?
4Because this is listed as Phase NA, which often applies to studies comparing existing procedures rather than new drugs, does that mean both the immediate and staged approaches are already considered acceptable standard care, and if so, why might joining this trial be better than just having my doctor choose one approach now?
5Are there other currently enrolling trials or established treatment guidelines for NSTE-ACS with multivessel disease that my doctor would recommend I consider while this trial is still in the pre-recruitment stage?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Major adverse cardiovascular and cerebrovascular event (MACCE)
. Patients in whom the culprit vessel cannot be clearly identified.
. Left main coronary artery lesion, non-infarct-related arteries are CTO lesions or severely calcified lesions, complex lesions that require the use of special devices such as rotational ablation/laser.
. Previous PCI within the past 1 month or previous coronary artery bypass graft (CABG).
. Accompanied by other diseases that lead to an expected survival time of ≤ 12 months.
. Patients with other serious diseases such as severe renal insufficiency (creatinine clearance value \<30ml/min), hepatic insufficiency, thrombocytopenia (≤50\*109/L).
. Patients with severe valvular disease, hypertrophic cardiomyopathy, restrictive cardiomyopathy, and primary pulmonary hypertension.